Published in J Neurooncol on January 01, 2005
Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J Neurooncol (2007) 2.85
A ligand-mediated nanovector for targeted gene delivery and transfection in cancer cells. Biomaterials (2008) 1.30
Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety. Curr Gene Ther (2009) 1.04
pH-Sensitive siRNA nanovector for targeted gene silencing and cytotoxic effect in cancer cells. Mol Pharm (2010) 1.03
Agents that bind annexin A2 suppress ocular neovascularization. J Cell Physiol (2010) 0.88
Chlorotoxin: a helpful natural scorpion peptide to diagnose glioma and fight tumor invasion. Toxins (Basel) (2015) 0.86
Recent advances in diagnosis and treatment of gliomas using chlorotoxin-based bioconjugates. Am J Nucl Med Mol Imaging (2014) 0.83
Clathrin-mediated entry and cellular localization of chlorotoxin in human glioma. Cancer Cell Int (2011) 0.80
pEGFP-N1-mediated BmK CT expression suppresses the migration of glioma. Cytotechnology (2012) 0.80
The Molecular Basis of Toxins' Interactions with Intracellular Signaling via Discrete Portals. Toxins (Basel) (2017) 0.75
Nanoparticle-Mediated Target Delivery of TRAIL as Gene Therapy for Glioblastoma. Adv Healthc Mater (2015) 0.75
Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res (2002) 4.58
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
Inhibition of cystine uptake disrupts the growth of primary brain tumors. J Neurosci (2005) 2.17
Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci U S A (1989) 2.15
Localization of iodine-125-mIP-Des-Met14-bombesin (7-13)NH2 in ovarian carcinoma induced to express the gastrin releasing peptide receptor by adenoviral vector-mediated gene transfer. J Nucl Med (1997) 2.05
Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol (2001) 1.87
CD133 is a marker of bioenergetic stress in human glioma. PLoS One (2008) 1.63
Use of chlorotoxin for targeting of primary brain tumors. Cancer Res (1998) 1.59
Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5. Int J Radiat Oncol Biol Phys (2008) 1.56
Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin Cancer Res (2006) 1.54
Blood volume redistribution during cross-clamping of the descending aorta. Anesth Analg (1994) 1.52
Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: implications for STAT-3 activation and gene expression. Clin Cancer Res (2008) 1.52
Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer. J Nucl Med (1992) 1.49
Cadmium-binding component in Escherichia coli during accommodation to low levels of this ion. Appl Environ Microbiol (1981) 1.49
Acid-sensing ion channels in malignant gliomas. J Biol Chem (2003) 1.38
Expression of human endogenous retrovirus k envelope transcripts in human breast cancer. Clin Cancer Res (2001) 1.38
Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma. J Clin Oncol (2006) 1.37
Tristetraprolin down-regulates interleukin-8 and vascular endothelial growth factor in malignant glioma cells. Cancer Res (2008) 1.36
Acquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chain. J Biol Chem (2010) 1.30
Lyn kinase activity is the predominant cellular SRC kinase activity in glioblastoma tumor cells. Cancer Res (2005) 1.29
Glucose metabolism heterogeneity in human and mouse malignant glioma cell lines. J Neurooncol (2005) 1.29
Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas. J Neurooncol (2003) 1.28
Focal adhesion kinase enhances signaling through the Shc/extracellular signal-regulated kinase pathway in anaplastic astrocytoma tumor biopsy samples. Cancer Res (2002) 1.26
Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model. Neuro Oncol (2005) 1.26
Therapeutic potential of AZD1480 for the treatment of human glioblastoma. Mol Cancer Ther (2011) 1.22
The RNA-binding protein HuR promotes glioma growth and treatment resistance. Mol Cancer Res (2011) 1.16
Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration. Clin Cancer Res (1999) 1.15
Surface expression of ASIC2 inhibits the amiloride-sensitive current and migration of glioma cells. J Biol Chem (2006) 1.15
Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. Cancer Res (2002) 1.14
Acquisition of chemoresistance in gliomas is associated with increased mitochondrial coupling and decreased ROS production. PLoS One (2011) 1.14
A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res (2002) 1.14
Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma. Cancer Res (1992) 1.12
Expression signature of IFN/STAT1 signaling genes predicts poor survival outcome in glioblastoma multiforme in a subtype-specific manner. PLoS One (2012) 1.11
Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study. Gynecol Oncol (1997) 1.10
A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin Cancer Res (2003) 1.09
Xanthine oxidase-dependent regulation of hypoxia-inducible factor in cancer cells. Cancer Res (2006) 1.07
Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12. J Virol (2012) 1.06
A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer. Cancer Biother Radiopharm (2001) 1.06
Proteomic identification of biomarkers in the cerebrospinal fluid (CSF) of astrocytoma patients. J Proteome Res (2007) 1.06
The role of DDX3 in regulating Snail. Biochim Biophys Acta (2011) 1.05
Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49. J Nucl Med (1996) 1.05
Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma. Hum Antibodies Hybridomas (1992) 1.05
Fas engagement increases expression of interleukin-6 in human glioma cells. J Neurooncol (2002) 1.02
Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12. Cancer Gene Ther (2005) 1.01
Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies. J Nucl Med (2005) 1.00
Herpes simplex virus oncolytic therapy for pediatric malignancies. Mol Ther (2009) 0.99
Genetically engineered herpes simplex viruses that express IL-12 or GM-CSF as vaccine candidates. Vaccine (2005) 0.98
Characterization of a mouse/human chimeric monoclonal antibody (17-1A) to a colon cancer tumor-associated antigen. J Immunol (1987) 0.98
Preclinical evaluation of ex vivo expanded/activated γδ T cells for immunotherapy of glioblastoma multiforme. J Neurooncol (2010) 0.97
Protein kinase C isoform antagonism controls BNaC2 (ASIC1) function. J Biol Chem (2002) 0.97
Monitoring method for surface contamination caused by selected antineoplastic agents. Am J Health Syst Pharm (2002) 0.96
Cancer Stem Cells and Pediatric Solid Tumors. Cancers (Basel) (2011) 0.96
Increased expression of thymidylate synthetase (TS), ubiquitin specific protease 10 (USP10) and survivin is associated with poor survival in glioblastoma multiforme (GBM). J Neurooncol (2006) 0.94
Expression of CEA, Tag-72, and Lewis-Y antigen in primary and metastatic lesions of ovarian carcinoma. Hum Pathol (2003) 0.94
Transcriptional targeting of adenovirally delivered tumor necrosis factor alpha by temozolomide in experimental glioblastoma. Cancer Res (2004) 0.93
Mouse/human chimeric antibodies to a tumor-associated antigen: biologic activity of the four human IgG subclasses. J Natl Cancer Inst (1988) 0.93
MARCKS regulates growth and radiation sensitivity and is a novel prognostic factor for glioma. Clin Cancer Res (2012) 0.93
Targeting pediatric cancer stem cells with oncolytic virotherapy. Pediatr Res (2012) 0.92
Characterization and immunotherapeutic potential of gammadelta T-cells in patients with glioblastoma. Neuro Oncol (2009) 0.92
Initial evaluation of human monoclonal anti-lipid A antibody (HA-1A) in patients with sepsis syndrome. Crit Care Med (1990) 0.91
Prognostic relevance of cytochrome C oxidase in primary glioblastoma multiforme. PLoS One (2013) 0.91
Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J Nucl Med (1994) 0.91
Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery. Bioconjug Chem (2003) 0.90
Cation selectivity and inhibition of malignant glioma Na+ channels by Psalmotoxin 1. Am J Physiol Cell Physiol (2004) 0.90
CD133 marks a myogenically primitive subpopulation in rhabdomyosarcoma cell lines that are relatively chemoresistant but sensitive to mutant HSV. Pediatr Blood Cancer (2012) 0.90
Oncolytic HSV-1 for the treatment of brain tumours. Herpes (2006) 0.89
Paclitaxel derivatives for targeted therapy of cancer: toward the development of smart taxanes. J Med Chem (1999) 0.89
Improved synthesis of the bifunctional chelating agent 1,4,7,10-tetraaza-N-(1-carboxy-3-(4-nitrophenyl)propyl)-N',N'',N'''-tri s(acetic acid)cyclododecane (PA-DOTA). Bioorg Med Chem (1999) 0.89
Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study. Cancer Biother Radiopharm (2001) 0.89
Targeting strategies for cancer radiotherapy. Clin Cancer Res (1999) 0.87
Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of neuroblastoma. PLoS One (2013) 0.87
Development of an HPLC method for simultaneous analysis of five antineoplastic agents. Appl Occup Environ Hyg (2003) 0.87
Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. I. Clinical aspects. J Natl Cancer Inst (1988) 0.87
Divergent effects of oncostatin M on astroglioma cells: influence on cell proliferation, invasion, and expression of matrix metalloproteinases. Glia (2006) 0.87
Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates. Hum Gene Ther Clin Dev (2014) 0.86
Pilot study using a humanized CC49 monoclonal antibody (HuCC49DeltaCH2) to localize recurrent colorectal carcinoma. Ann Surg Oncol (2004) 0.85
Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation. Mol Cancer Ther (2002) 0.85
Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131I-labeled monoclonal antibody CC49. Cancer Res (1995) 0.84
Phase II study of dual 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer. Clin Cancer Res (1996) 0.84
Phase I clinical trial of CO17-1A monoclonal antibody. Hybridoma (1986) 0.84
A new monitoring method using solid sorbent media for evaluation of airborne cyclophosphamide and other antineoplastic agents. Appl Occup Environ Hyg (2003) 0.84
Quinacrine synergistically enhances the antivascular and antitumor efficacy of cediranib in intracranial mouse glioma. Neuro Oncol (2013) 0.83
Phase I trial of an anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: effect of an intensive schedule of administration. J Immunother Emphasis Tumor Immunol (1995) 0.83
Growth-inhibitory effects of coumarin (1,2-benzopyrone) and 7-hydroxycoumarin on human malignant cell lines in vitro. J Cancer Res Clin Oncol (1994) 0.83
Polymerase chain reaction for the rapid detection of cerebrospinal fluid shunt or ventriculostomy infections. Neurosurgery (2005) 0.83
A phase I clinical trial of murine monoclonal antibody D612 in patients with metastatic gastrointestinal cancer. Cancer Res (1993) 0.83
Idiotypic vaccination with a murine anti-dsDNA antibody: phase I study in patients with nonactive systemic lupus erythematosus with nephritis. J Rheumatol (1999) 0.83
Downregulation of FIP200 induces apoptosis of glioblastoma cells and microvascular endothelial cells by enhancing Pyk2 activity. PLoS One (2011) 0.83
Pharmacologic manipulations of mitochondrial membrane potential (DeltaPsim) selectively in glioma cells. J Neurooncol (2006) 0.83
Enhancement of radiolabeled antibody binding and tumor localization through adenoviral transduction of the human carcinoembryonic antigen gene. Gene Ther (1996) 0.83
Engineered drug resistant γδ T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy. PLoS One (2013) 0.83
Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein. Cancer Biother Radiopharm (2005) 0.82
CMV-independent lysis of glioblastoma by ex vivo expanded/activated Vδ1+ γδ T cells. PLoS One (2013) 0.82
Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer. Clin Cancer Res (1999) 0.82
Pediatric glioma stem cells: biologic strategies for oncolytic HSV virotherapy. Front Oncol (2013) 0.82
Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy. J Nucl Med (2002) 0.81